AURINIA PHARMACEUTICALS
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the potential treatment of lupus nephritis, focal segmental glomerulosclerosis, and Dry Eye Syndrome.
AURINIA PHARMACEUTICALS
Industry:
Biopharma Biotechnology Health Care Medical Therapeutics
Founded:
2011-01-01
Address:
Victoria, British Columbia, Canada
Country:
Canada
Website Url:
http://www.auriniapharma.com
Total Employee:
251+
Status:
Active
Contact:
+1 (250) 744-2487
Email Addresses:
[email protected]
Total Funding:
658.46 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Apache
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2013-02-05 | Isotechnika Pharma | Isotechnika Pharma acquired by Aurinia Pharmaceuticals | N/A |
Investors List
Apple Tree Partners
Apple Tree Partners investment in Post-IPO Equity - Aurinia Pharmaceuticals
Lumira Ventures
Lumira Ventures investment in Post-IPO Equity - Aurinia Pharmaceuticals
Redmile Group
Redmile Group investment in Post-IPO Equity - Aurinia Pharmaceuticals
ILJIN Life Science
ILJIN Life Science investment in Post-IPO Equity - Aurinia Pharmaceuticals
Difference Capital
Difference Capital investment in Post-IPO Equity - Aurinia Pharmaceuticals
Great Point Partners
Great Point Partners investment in Post-IPO Equity - Aurinia Pharmaceuticals
New Enterprise Associates
New Enterprise Associates investment in Post-IPO Equity - Aurinia Pharmaceuticals
RA Capital Management
RA Capital Management investment in Post-IPO Equity - Aurinia Pharmaceuticals
venBio Partners
venBio Partners investment in Post-IPO Equity - Aurinia Pharmaceuticals
Lumira Ventures
Lumira Ventures investment in Post-IPO Equity - Aurinia Pharmaceuticals
Official Site Inspections
http://www.auriniapharma.com Semrush global rank: 1.9 M Semrush visits lastest month: 11.51 K
- Host name: ec2-174-129-30-187.compute-1.amazonaws.com
- IP address: 174.129.30.187
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149